LERN’s ongoing development of Louisiana’s statewide stroke care system is guided by the evidence-based “hub and spoke” model that facilitates widespread patient access to lifesaving care and treatment with tissue plasminogen activator (tPA), the only FDA approved medication for treatment of an occlusive stroke within the first few hours.

Louisiana’s “hub and spoke” model includes Comprehensive Stroke Center and Primary Stroke Center hubs, and spoke hospitals connected by telemedicine.

Click here for LERN White Paper: Building a Stroke System in Louisiana